Logo

AbbVie Reports Results of ABBV-951 (foslevodopa/foscarbidopa) in P-III M15-736 Study for the Treatment of Advanced Parkinson's Disease

Share this
AbbVie Reports Results of ABBV-951 (foslevodopa/foscarbidopa) in P-III M15-736 Study for the Treatment of Advanced Parkinson's Disease

AbbVie Reports Results of ABBV-951 (foslevodopa/foscarbidopa) in P-III M15-736 Study for the Treatment of Advanced Parkinson's Disease

Shots:

  • The P-III M15-736 Study evaluates the efficacy, safety & tolerability of ABBV-951 to levodopa/carbidopa in 130 adult patients with advanced PD across 80 sites globally
  • The study met its 1EPs of increase from baseline in "On" time (hours) without troublesome dyskinesia after 12wks. based on PD Diary. The therapy also showed an improvement from baseline in hrs. of average daily normalized "Off" time that followed a similar pattern in reductions after 1st wks. through 12wks. & was superior to levodopa/carbidopa in reducing motor fluctuations
  • Additionally, AEs were consistent with the well-established safety profile of levodopa/carbidopa, treatment discontinuation due to AEs (21.6% & 1.5%)

 Ref: AbbVie | Image: Linkedin

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions